Fine chemical earnings grow at Albemarle in Q2

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology, Revenue, Active ingredient

Albemarle second quarter results fine chemicals
Fine chemicals were one of few positives for Albemarle in the second quarter according to the US chemicals firm’s latest results.

The fine chemicals unit – which combines Albemarle’s generic active pharmaceutical ingredients (API) business, its chemistry services division and its agri chemicals group– saw net sales increase 13 per cent in the three months to June 30 to $208.7m (€170.4m) and income grow 17 per cent.

This contrasts with Albermarle’s catalysts and polymer solutions divisions which saw net sales decline 14 and 15 per cent respectively with income falling 2 per cent and 17 per cent.

Albemarle is due to hold its earnings conference call later today and has not yet said what drove the fine chemicals growth, other than to attribute it “to favourable volumes and pricing​.”

Pharmaceutical contribution?

The result continues the trend seen in the first quarter​ when Albemarle COO John Steitz said that ‘positive trends within its pharmaceutical portfolio’ had played a part in increasing fine chemicals profitability and improving margins.

At the time he told investors that: “The impact of evolving our portfolio towards complex, higher margin, longer duration opportunities was evident during the [first] quarter as operating margins rose impressively​.”

The story was the same in the final quarter of 2011 - which saw fine chemicals revenue grow 36 per cent with Steitz describing the firm's specialty pharmaceutical chemicals activities as important​. 

Whether sales to the drug industry have had as big a positive impact in Q2 2012 remains to be seen, but Albemarle’s recent activities certainly suggest that it views the sector as an increasingly important part of its business.

In May​ Albemarle increase its prices for ibuprofen – one of its top selling generic APIs – and more recently the firm increase production capacity at its actives plant in South Haven, Michigan citing growing drug industry demand​ and a desire to further advance its pharma portfolio.

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more